Viracta is a clinical-stage drug development company committed to advancing new medicines based on its proprietary viral gene activation therapy approach to benefit patients with viral-associated cancers and other serious diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/04/17 | $18,400,000 | Series B |
Forward Ventures Latterell Venture Partners NantKwest  Wicklow Capital | undisclosed |
| 10/28/19 | undisclosed | Series D |
Taiwania Capital Management Corporation | undisclosed |
